DETAILED ACTION
Claims 1-10 are currently pending and are examined on the merits herein.
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Application Priority
This application filed 10/09/2024 claims foreign priority CHINA 202311379825.4 filed on 10/23/2023.
Information Disclosure Statement
The information disclosure statement(s) (IDS) filed on 10/9/2024 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the IDS is being considered by the Examiner.
The following rejections are made:
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-10 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Song et al. (WO2021217826 A1).
The instant claims are drawn to “a method for dimyricetin-yl- diselenide in the preparation of a medicament” and “a method for inhibiting the growth of tumor cells in vitro in non-therapeutic manner.”
Song et al. teaches drug preparation and application of dimyricetin-based diselenide represented by a molecular structure formula (1) in the treatment of tumors and resistance of new coronavirus (2019-nCoV); wherein the tumor comprises liver cancer, lung cancer, primary colorectal cancer, cervical squamous cell carcinoma, gastric cancer, prostate cancer, and lung adenocarcinoma. (claims 1-2). The reference teaches inhibitory effects on 7 different human-derived tumor cells including HEP3B2.1.7 (hepatocellular carcinoma). (abstract) Table 4 that dimyricetin-based diselenide has obvious inhibitory effects on human liver cancer cells, human lung cancer cells (large cell lung cancer), primary colorectal cancer cells, human cervical squamous cells, human gastric cancer cells, human prostate cancer cells, human lung adenocarcinoma cells (pleural effusion). [0042]
PNG
media_image1.png
318
538
media_image1.png
Greyscale
Conclusion
No claims allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAYLA SOROUSH whose telephone number is (571)272-5008. The examiner can normally be reached on Monday thru Friday; 8:30 AM to 5:00 PM EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http:/Awww.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Henry Alstrum-Acevedo, can be reached on (571)272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/LAYLA SOROUSH/ Primary Examiner, Art Unit 1622
Prosecution Insights